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Objectives: The aim of this study is to show that the historical data, through
genealogies, can help understanding the spreading process of the CFTR mutations
on a determined territorial area.
Methods: The panel is composed of 1264 CF patients. 674 were born or have lived
in Brittany within the past 50 years. Since these patients have been taken care of
by local caring centers, we know all their diagnostic and clinical characteristics.
Moreover, thanks to the registry ofﬁce and the local archives we have managed
to follow their direct line ancestors, leading to the identiﬁcation of an ancestral
population of 60000 individuals.
The database, validated by the CNIL, is endowed with an algorithm which can ﬁnd
the parental relationships between the individuals.
The results presented in this study are limited to the genealogical links found
between the 6 patients who carry the 1717−1G→A mutation in the heterozygous
compound state, used here as an example because no ancestral study was made in
carriers of this mutation.
Conclusions: 4 out of the 6 patients have been aggregated to the 13th generation,
to a founder couple living in the 17th century in the Breton town of Plouhinec.
Nevertheless, the other 2 patients do not have all their ancestors localized in Brittany
and do not seem to be related.
Due to the same origins of the mutations, a classiﬁcation can thereby be established,
between “family forms” and “theoretically sporadic forms” of CF, where one of the
practical applications is to guide the genetic advice given to the families.
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With the increasing knowledge of CF and CFTR-related diseases (CF-RD) the
number of sequence variations in the CFTR gene is constantly raising. CF and
particularly CFTR-RD provide a particular challenge for molecular diagnostic
because of many unclassiﬁed (missense or putative splice site) variants and identical
genotypes associated with different phenotypes. An exhaustive and manually-
curated database (containing not only disease-causing genotypes but also haplo-
types) is crucial for accurate interpretation of pathogenicity.
Using the Universal Mutation Database (UMD®) software, a freely available tool
internationally recognized, we have constructed the UMD-CFTRbase dedicated to
sequence variations of the CFTR gene. The UMD-CFTRbase currently contains
molecular data on 771 patients studied in our laboratory: 541 CF and 216 CFTR-
RD. Besides disease-causing mutations, the database contains unclassiﬁed variants
and non-pathogenic polymorphisms (252 different sequence variations) representing
3900 entries.
Tools, such as UMD-Predictor, are provided to assess the pathogenicity of mutations
(combining splicing effect, conservation, biochemistry and structure of amino acids)
and integrate haplotypes. UMD-CFTR is unique as it offers a way to compile
any mutational data of the CFTR gene in order to help the contributing scientiﬁc
community to improve sequence variation interpretation, evaluate the putative
inﬂuence of haplotypes on mutations and correlate with phenotypes.
We are now collecting and curating data from 9 expert laboratories. The large
amount of information collected from CF or CFTR-RD patients will increase the
power of analysis of correlations between genotype/haplotype and phenotype.
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Works on setting up Polish National CF Registry has been pursued for the last
few years. The preliminary data have been collected from 20 centers. Three and
two centers care exclusively for children or adults, respectively. The remaining 15
centers provide care for patients with no regard to age. Six centers care for more
than 50 patients. There are 1303 patients registered at present, among them 1250 are
alive. 30% of patients are adults. In a signiﬁcant percentage of subjects diagnosis
was made in early childhood − in 61% within ﬁrst year of life. Late diagnosis
is rather scarce, only 1.4% of patients were diagnosed as grown-ups. F508del is
predominant mutation and was found on 69% of alleles. 47% of all patients were
homozygous for this mutation. Consecutive mutations in terms of frequency are:
3849+10kbC-T(6%), N1303K(4%), G542X(4%), 1717−1G-A(3%). 21% of subjects
are pancreatic sufﬁcient while remaining 79% of patients have severe exocrine
insufﬁciency resulting in steatorrhea. In registered clinical assessments, the presence
of Pseudomonas aeruginosa infection was proved in 60% of patients. In 62% it
was mucoid strain, in 36% – non-mucoid and 3% – drug resistant. Gastrostomy
was placed and vascuport was implemented in 2% and 5% of patients, respectively.
Supported by: Roche Poland (in part).
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The Aristotle University Cystic Fibrosis (CF) Center consists of two paediatric
and an adult CF Unit in Thessaloniki, using the same protocols, serving a whole
population of about 2.5 million inhabitants living in Northern Greece.
Aim: To evaluate the epidemiologic data of CF in Northern Greece.
Method: Demographic, genetic and clinical symptoms were collected in a database,
according to the European CF Registry. Data collection was completed in a three-
months period (February-April 2008). All the information was obtained from
patients’ clinical notes.
Results: Totally 191 CF patients (both children and adults) were identiﬁed with
mean age 16.81±9.21 years. The older CF patient was 40 years old, while 43.5%
of patients were older than 18 years. Mean age of diagnosis was 1.16±0.53 years.
Eighty percent of patients were identiﬁed with the DF508 mutation (23.75%
were homozygous). Thirty percent of our patients were chronically colonized
with Pseudomonas aeruginosa; Burkholderia cepacia was not isolated in any
of our patients. 94% had pancreatic insufﬁciency and 30% were malnourished
(BMI< 18.5 kg/m2), 3.66% had meconium ileus and 3% had CFRD. The FEV1
among patients aged 6−18 years, was 90.67±29.28%, while the FEV1 among older
patients (>18 years) was 68.64±25.87%. None of our patients had undergone lung
or liver transplantation.
Conclusions: In the ﬁrst Registry of Greek patients with CF, the health status of
the patients is presented.
